Deerfield Management Company Lowered Sangamo Therapeutics (SGMO) Position By $6.62 Million; Last Week Rightmove plc (LON:RMV) Analysts

February 20, 2018 - By Marguerite Chambers

Deerfield Management Company decreased Sangamo Therapeutics Inc (SGMO) stake by 40.33% reported in 2017Q3 SEC filing. Deerfield Management Company sold 441,305 shares as Sangamo Therapeutics Inc (SGMO)’s stock rose 95.00%. The Deerfield Management Company holds 653,000 shares with $9.80 million value, down from 1.09 million last quarter. Sangamo Therapeutics Inc now has $1.93 billion valuation. The stock decreased 1.93% or $0.45 during the last trading session, reaching $22.85. About 659,615 shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 29.78% since February 20, 2017 and is uptrending. It has outperformed by 13.08% the S&P500.

Among 21 analysts covering Rightmove PLC (LON:RMV), 6 have Buy rating, 5 Sell and 10 Hold. Therefore 29% are positive. Rightmove PLC had 160 analyst reports since July 29, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, July 27 by Numis Securities. Barclays Capital maintained Rightmove plc (LON:RMV) on Monday, September 12 with “Underweight” rating. Numis Securities maintained it with “Buy” rating and GBX 4070 target in Thursday, July 30 report. The rating was maintained by Liberum Capital on Friday, February 26 with “Buy”. Goldman Sachs maintained Rightmove plc (LON:RMV) on Friday, January 13 with “Neutral” rating. As per Monday, June 26, the company rating was maintained by Jefferies. As per Thursday, July 30, the company rating was maintained by Deutsche Bank. The rating was maintained by Peel Hunt with “Hold” on Wednesday, January 17. On Monday, February 27 the stock rating was maintained by Liberum Capital with “Buy”. The firm has “Buy” rating given on Wednesday, October 28 by Canaccord Genuity. See Rightmove plc (LON:RMV) latest ratings:




06/02/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 4400.00 New Target: GBX 4400.00 Maintain
31/01/2018 Broker: Deutsche Bank Rating: Hold Maintain
29/01/2018 Broker: Barclays Capital Rating: Underweight Old Target: GBX 3700.00 New Target: GBX 4000.00 Maintain
25/01/2018 Broker: Deutsche Bank Rating: Hold Old Target: GBX 4000.00 New Target: GBX 4000.00 Maintain
23/01/2018 Broker: Goldman Sachs Rating: Sell Old Target: GBX 3959.00 New Target: GBX 4280.00 Downgrade
18/01/2018 Broker: JP Morgan Rating: Underweight Old Target: GBX 4183.00 New Target: GBX 4168.00 DownGrade
17/01/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 4000.00 New Target: GBX 4400.00 Maintain
15/01/2018 Broker: Liberum Capital Rating: Buy Old Target: GBX 5000.00 New Target: GBX 5000.00 Maintain
19/12/2017 Broker: Liberum Capital Rating: Buy Old Target: GBX 5000.00 New Target: GBX 5000.00 Maintain
04/12/2017 Broker: Deutsche Bank Rating: Hold Old Target: GBX 4000.00 New Target: GBX 4000.00 Maintain

The stock increased 0.39% or GBX 17 during the last trading session, reaching GBX 4330. About 201,072 shares traded. Rightmove plc (LON:RMV) has 0.00% since February 20, 2017 and is . It has underperformed by 16.70% the S&P500.

Rightmove plc operates property portal in the United Kingdom. The company has market cap of 3.93 billion GBP. The firm operates through Agency, New Homes, and Other divisions. It has a 29.99 P/E ratio. The Agency segment offers resale and lettings property advertising services on its platforms.

Since September 1, 2017, it had 0 buys, and 8 selling transactions for $1.88 million activity. On Thursday, February 1 the insider Herberts Curt A. III sold $308,855. 5,000 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares with value of $85,545 were sold by Conner Edward R.. RINGO WILLIAM R sold $445,597 worth of stock or 31,000 shares. Mento Steven J sold $237,159 worth of stock.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on February, 27. They expect $-0.18 earnings per share, down 28.57% or $0.04 from last year’s $-0.14 per share. After $-0.15 actual earnings per share reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Sangamo Biosciences had 22 analyst reports since August 8, 2015 according to SRatingsIntel. As per Wednesday, September 2, the company rating was maintained by Wedbush. JP Morgan maintained the shares of SGMO in report on Saturday, August 8 with “Overweight” rating. Piper Jaffray maintained the shares of SGMO in report on Wednesday, January 3 with “Buy” rating. The firm has “Sell” rating by Zacks given on Tuesday, September 8. Jefferies reinitiated Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Friday, October 23 with “Buy” rating. Jefferies maintained the stock with “Buy” rating in Tuesday, September 12 report. The firm has “Buy” rating by JP Morgan given on Thursday, September 3. The firm earned “Buy” rating on Friday, October 13 by Jefferies. The rating was maintained by Piper Jaffray with “Hold” on Thursday, August 10. The firm earned “Neutral” rating on Wednesday, October 19 by Piper Jaffray.

Deerfield Management Company increased Agile Therapeutics Inc (NASDAQ:AGRX) stake by 266,666 shares to 1.22 million valued at $5.45 million in 2017Q3. It also upped Ascendis Pharma A S stake by 430,547 shares and now owns 850,000 shares. Alimera Sciences Inc (NASDAQ:ALIM) was raised too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: